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Characterization of Novel Nitroplatinum (IV) Complexes for the Treatment of Cancer
Jeannette Lo
ABSTRACT
Many types of chemotherapeutic agents have been developed to target specific
mechanisms within the body that control the progression of cancer, though few have been
able to circumvent the existing problems associated with the treatments. The current
remedies entail grueling drug regimens and toxic side effects that may undermine the
effectiveness of the drugs. Cisplatin, a common nitroplatinum(II) drug widely used to
treat a variety of cancers, is administered intravenously and circulates systemically,
affecting healthy regions of the body as well. Resistance to cisplatin is increasing and the
need for new, less toxic medication must be met for future success in cancer therapy.
Our lab has synthesized novel nitroplatinum(IV) cisplatin complexes (PH1-14) that may
evade these problems. We examined the effects of these compounds on cell viability, as
well as effects on cancer-specific mechanisms such as nitric oxide (NO) production,
angiogenesis, and the STAT signaling pathways. In vitro studies demonstrated that PH111 and PH14 demonstrated greater efficacy at inhibiting cell proliferation with lower
IC50 values that ranged from 41-58 uM (as compared with cisplatin IC50 = 66 uM). Data
from NO assays were inconclusive, though there was elevated expression of inducible
nitric oxide synthase in cells treated with PH3 and PH11. We also found that PH9 was
able to inhibit STAT dimerization at concentrations as low as 0.3 uM. PH9 also
decreased VEGF and HIF-1α expression, thereby inhibiting angiogenesis. The activity of
vii

the PH complexes was also studied in C57BL/6 mice inoculated with murine bladder
MB49 tumors. The experimental group showed significantly slower tumorigenesis and
smaller tumors as compared with the control group. Toxicological analyses of the blood
via metabolic assays showed that no nephrotoxicity was observed in dosages of less than
7 mg drug/kg. We conclude from these results the potential for the use of novel
mechanisms in the treatment of cancers. This work will guide future investigations of
these drugs in further preclinical trials and also introduce an alternative to the traditional
chemotherapeutic agents.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE

1.1

Chemotherapy
Chemotherapy is the use of chemotherapeutic agents for the cure, control,

and palliation of cancer. Its use has been documented since the 16th century, when heavy
metals were used systemically to treat cancers, often causing severe toxicity with limited
clinical improvement. Today, chemotherapy is one of the most commonly used
treatments for cancer. A wide range of chemotherapeutic drugs have been discovered
and are available as treatment, including plant alkaloids, alkylating agents, hormones, and
antibiotics. [1]. Continuous research has allowed new drugs to emerge frequently,
undergoing clinical trials before being accessible to the public.
Many types of chemotherapeutic agents have been developed to target
specific mechanisms within the body that control the progression of cancer. Cell-cycle
specific agents, such as Paclitaxel, can arrest metaphase by interfering with the formation
of the mitotic spindle. Antimetabolites, such as Floxuidane, are another group of cellcycle specific agents that act by replacing components essential to the metabolic
synthesis of DNA during the S phase. Alkylating agents, such as cisplatin, interrupt
replication of genetic material by cross-linking and strand-breaking DNA, leading to cell
lysis. Antitumor antibiotics, such as Doxirubicin, prevent cell division by damaging the
cell and interfering with DNA and RNA syntheses. Hormones or hormone-like agents,
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such as estradiol, inhibit tumor growth by antagonizing the otherwise naturally occurring
ligands from their receptors and initiating tumor proliferation [1].

1.2 Platinum Complexes
Cisplatin, a widely used chemotherapeutic agent for the treatment of
testicular, ovarian, head and neck, stomach, and bladder carcinomas, is a platinum(II)
complex that was discovered in 1972 [2]. Cisplatin can bind to RNA, proteins, and other
sulfur-containing biomolecules, though its main biological target is DNA [3-5]. It forms
1,2-intrastrand guanine-guanine, and guanine-adenine crosslinks, accounting for
approximately 90% of the resulting adduct. The remaining interactions involve 1,3intrastrand and interstrand adducts. Its primary crosslink structures serve as a recognition
motif for an array of biological molecules, including DNA repair elements, histones, and
serum proteins [4, 6]. The formation of these adducts result in blocked transcription,
replication inhibition, and apoptosis [3]. However, there are major limitations to cisplatin
in anticancer therapy [7].
As a platinum(II) complex, cisplatin circulates systemically in a
chemically active state, causing significant side effects including nausea and vomiting,
renal toxicity, and bone marrow damage [2, 4, 7-9]. Another limitation to cisplatin is the
emergence of resistance to cisplatin during treatment. Studies have reported several
modes of resistance such as reduced drug uptake, increased drug inactivation [10, 11],
altered drug targets, altered gene expression [12-14], and loss of the DNA mismatch
repair (MMR) mechanism [15]. The MMR system plays a critical role in ensuring
genomic stability by correcting damaged DNA. MMR is mediated by directing a nick
2

Figure 1.1 Example structures of platinum(II) and platinum(IV) complexes.

located 5’ or 3’ to the mismatch. Exonucleated degradation is initiated from the nick to
the mismatched base. The DNA that contains the mismatch is then removed,
resynthesized, and sealed. In normal cells, MMR recognizes DNA damage and initiates
DNA repair or apoptosis. In resistance cells, the MMR system is lost. This decrease in
signaling for repair or apoptosis results in increased survival for drug-treated cells [15].
The loss of DNA MMR resulting in cisplatin-resistant cell lines has been documented
[16-18].
Improved, platinum-based treatments have emerged. Carboplatin, another
platinum(II) drug, was developed to decrease systemic toxicity and resistance observed
with cisplatin. However, as compared to cisplatin, carboplatin has inferior efficacy in
treating head and neck, bladder, and oesophageal cancers [19]. An alternative to the
existing toxic platinum(II) complexes was needed, leading to the development of
platinum(IV) complexes. The octahedral platinum(IV) complex are more inert to serum
blood proteins as they travels through the body. Then, upon reaching the tumor site,
3

reduction to a square-planar platinum(II) complex allows the complex to bind to DNA
[6]. Ideally, a drug maintaining these properties can be a potent anti-tumor agent with
reduced toxic side effects. Additionally, some studies have shown that platinum(IV)
complexes can bind to DNA without prior reduction [20, 21].
JM216 (Satraplatin), a platinum(IV) complex, entered clinical trials in
1992 on the basis of possessing several promising preclinical features. It demonstrated
potent in vitro and in vivo growth inhibitory properties against several tumor varieties,
and has relatively mild toxicity profile with myelosuppression being dose-limiting [22].
Satraplatin is now undergoing investigation in Phase III clinical trails. Zak et al [7] tested
another platinum(IV) drug, LA-12, against cisplatin resistant tumor lines and found that
LA-12 demonstrated lower IC50’s as compared with cisplatin, but had not yet established

Figure 1.2 Platinum complexes designed for the treatment of cancer [2, 7, 9].

studies for toxicity yet. Tetraplatin, another platinum(IV) analogue, entered Phase I
clinical trials to assess toxicities and to determine a maximum tolerated dose. Nausea,
vomiting, and myelosuppression were moderate, but neurotoxicity was symptomatic inall
patients and caused significant functional impairment some patients, thus ending further
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clinical trials [23]. Investigations of additional platinum(IV) complexes are currently in
progress.
1.3

Targets and Mechanisms of Cancer Management

1.3.1

Angiogenesis
A cell must have fundamental methods of obtaining nourishment from the

body to maintain its health and vitality. Blood vessels facilitate this by carrying oxygen
and nutrients to a cell, while removing waste products. Angiogenesis, or the formation of
new blood vessels, is usually unique to new or developing tissues. In a healthy adult,
emergence of vessels may occur for repair or reproduction but has a limited role.
However, in cancer, angiogenesis is integral to its growth. A tumor acquires its own
blood supply to sustain its development.
Vascular endothelial growth factor (VEGF) is a pro-angiogenic factor that
has been implicated in tumor angiogenesis [24]. Hypoxic inducible factor-1 (HIF-1) is
also known to mediate transcription of the gene for VEGF [25]. HIF-1 also plays a role
in tumor angiogenesis by mediating P13K/AKT-induced VEGF expression [26-28],
pathways that are often found to aberrant in cancers. HIF-1 is a heterodimer comprised
of the oxygen-regulated inducible subunit HIF-1α, and a constitutively active HIF-1β
[28]. Overexpression of HIF-1α is associated with tumor angiogenesis and tumor cell
proliferation and invasion. Drugs that promote inhibition of VEGF have been studied as
potential anti-cancer agents [29-31]. Bevacizumab, a recombinant humanized
monoclonal antibody directed to VEGF, has been shown in clinical studies to inhibit
tumor neovascularization, and thus tumor growth [24]. This suggests that development
5

of further chemotherapeutic agents targeting VEGF and its related regulators may be
useful in cancer therapy.

1.3.2

Signal Transducers and Activators of Transcription (STAT)
Growth factors are secreted extracellularly and bind to receptors on cell

membranes to initiate messages to grow or differentiate. Once the growth factor binds, it
sets off a cascade of intracellular signaling that may dictate the production of specific
protein or gene products, eventually leading to transcription. In cancer, a disruption of
this communication system can lead to errors in the under/overproduction of protein
products, causing aberrant signaling. Key signaling pathways have been implicated in
many cancers.
Signal transducers and activators of transcription (STAT) proteins are a
family of cytoplasmic transcription factors that function as downstream effectors of
cytokine and growth factor receptor signaling. These proteins transmit signals to the
nucleus where STATs bind to DNA and induce gene expression [32-36]. Seven STAT
family members have been identified: STAT1, STAT2, STAT3, STAT4, STAT5a,
STAT5b, and STAT6 [37]. Numerous studies have shown that constitutively activated
STAT1, STAT3, and STAT5 are present in many human cancers [38]. Futhermore,
aberrant STAT3 signaling contributes to tumor development through mechanisms of
increased cell proliferation. STAT activation occurs when tyrosine kinase activities
phosphorylate receptor-bound STATs. The phosphorylated STAT proteins undergo
dimerization and translocate to the nucleus, where they bind to specific DNA promoter
sequences and induce gene expression [38]. Constitutively active STAT proteins
6

continue this cascade, resulting in uncontrolled cell proliferation. The use of a
chemotherapeutic agent to inhibit STAT dimerization can potentially be a useful
technique to treat cancer.

Figure 1.3 Schematic of STAT signaling [39].

1.3.3

Biological Effects of Nitric Oxide
Nitric oxide (NO) plays a biological role in many pathologies, including

diabetes, hypertension, and male impotence. Increasing evidence suggests that NO may
also have an effect on cancer biology [40]. Activation of nitric oxide synthase (NOS) and
its subsequent release of NO can cause cytostasis [41-43]. It has also been reported that
NOS represents a significant macrophage antitumor mechanism [44]. Peroxynitrite, a
reaction product of NO with O2−, can damage cells [45] and induce apoptosis in a
7

concentration-dependent manner [46, 47]. Xie and Fidler [48] found that tumor cells that
were capable of producing very high levels of NO died in vivo, while those cells that
produced or were subjected to low levels of NO lived on to undergo clonal selection.
There are several mechanisms for the action of NO, some of which are
mediated through the inhibition of DNA synthesis and mitochondrial respiration [49].
This is achieved via interaction with intracellular iron-sulfur prosthetic groups of
Complex I and II of the mitochondrial electron transport system together with the citric
acid enzyme aconitase, and non-heme iron of ribonucleotide reductase [50-52].
Conflicting data indicate that macrophage infiltration into malignant tissue
has been correlated with both a decrease in metastasis and an increase in cell survival [43,
53, 54] However, recent studies suggest that NO may also assist macrophages in their
battle against cancer. Several groups found that NO production was a major cytotoxic
effector mechanism of macrophages [55-57]. It allowed macrophages to acquire potent
antitumor activities after exposure to cytokines.
Additionally, NO can augment the effects of chemotherapy and radiation.
Wink et al [58] found that NO can enhance the effect of cisplatin in Chinese hamster V79
cells by inhibiting the DNA repair mechanism. This data supports results from a study by
Azizzadeh [59], who also found improved cytotoxicity in Chinese hamster lung
fibroblasts using long-acting NO donors. Effects of NO with other drugs have also been
reported. Cook et al [60] found that the anticancer action of melphalan improved with
NO, while Adams et al [61] discovered that cytotoxic effects of the antimetabolite
fludarabine was more potent in human chronic lymphocytic leukemia cells when used
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with a NO-donating drug. Radiation therapy has also been found to be enhanced when
used in conjunction with NO, due to improved sensitivity to radiation from the cells [62].

1.3.4

Novel Nitroplatinum(IV) Complexes
Our aim in the development of novel nitroplatinum(IV) complexes was to

decrease systemic toxicity and resistance, and increase anti-tumor activities through the
addition of two ligands to the current square-planar cisplatin structure. Oxidation
produces a platinum(IV) complex that has been reported to be able to evade the
mechanisms of multi-drug resistance [63-66] and reduce clinical toxicity [2, 3, 65, 67,
68]. This new group of platinum(IV) compounds can circumvent the drug-resistance
commonly observed with traditional anti-cancer agents such as cisplatin. They may
prevent the direct extrusion of cytotoxic drugs from the cell, or may act by inhibiting the
sequestering of the drugs into intracellular compartments, thereby reducing effective
intracellular drug concentrations [69]. The prevention of these self-preserving actions
can lead to successful drug administration.
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CHAPTER 2: EXPERIMENTAL DESIGN

2.1

In vitro studies

2.1.1

Drug Synthesis
In compliance with the regulations of patents and licensing, the details of

synthesis of these platinum(IV) complexes under patents #03B100 and #03B005 cannot
be disclosed at this time.
2.1.2 Cell Culture
The human lung carcinoma cell line A549 was generously provided by Dr.
George Blanck (Dept. of Biochemistry, College of Medicine, USF). Frozen cells were
thawed at 23˚C and grown in 45% Dulbecco’s Modified Eagle Medium:45% Ham’s F12
Medium:10% Newborn Calf Serum (Fisher Scientific). L-glutamine, penicillinstreptomycin, and sodium pyruvate (Fisher Scientific) were added to media for final
concentrations at 3 mM, 100 U/mL, and 1 mM, respectively. Media was filter-sterilized
using vacuum filtration through a polyethersulfone membrane of 0.2 micron pore size.
Cells were grown in canted-neck vented-cap tissue culture flasks (BD Falcon) in a 37˚C
incubator (NuAire) with 7.5% CO2 and seeded at confluence.
2.1.3

Drug treatment
Cells in log phase were seeded at 90-100% confluence. Cells were

washed twice with 1x phosphate buffered saline (PBS), then lysed from culture flasks
10

with trypsin-versene (Cambrex Bio Science). Cells were seeded into 96-well tissue
culture plates (growth area per well = 0.32 cm2) at a density of 2.5 x 105 cells per well.
Drug and media were added to the wells in varying concentrations for a final total
volume of 200 uL per well. Culture plates were then incubated for 48 hours at 37˚C with
7.5% CO2. Each treatment condition was performed in triplicate. Controls contained
only cells and media.

Table 2.1. Schema of drug treatment at various dilutions.
Treatment Condition
Control
10 uM drug
20 uM drug
25 uM drug
30 uM drug
40 uM drug
50 uM drug
60 uM drug
70 uM drug
75 uM drug

2.1.4

Cell volume (uL)
100
100
100
100
100
100
100
100
100
100

Media (uL)
100
90
80
75
70
60
50
40
30
25

Drug volume (uL)
0
10
20
25
30
40
50
60
70
75

XTT Cell Viability Assay
Cell viability was determined using the tetrazolium salt XTT [2,3-bis-(2-

methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- carboxanilide, disodium salt] Cell
Proliferation Kit (MD Biosciences, Switzerland). The XTT assay is a biochemical
procedure that allows for the assessment of viable cells. Mitochondrial dehydrogenases
in metabolically active cells cleave the tetrazolium ring, producing a water-soluble

11

orange formazan dye. The amount of dye produced is proportional to the number of live
cells. This dye can then be measured using a spectrophotometer [67].
After drug treatment as described in section 2.1.3, the XTT reagent was
prepared by adding 0.2 ml of the PMS (N-methyl dibenzopyrazine methyl sulfate)
activation reagent to 10 ml of the XTT reagent. This produced enough reaction mixture
for the analysis of one 96-well plate. One-hundred microliters of the XTT reaction
solution was added to each well (final XTT concentration = 0.3 mg/ml). Plates were
incubated for an additional 2-5 hours at 37˚C with 7.5% CO2. The plates were then
agitated on a plate shaker for approximately 5 minutes and immediately analyzed for
absorbance at 475 nm using a UV-Visible spectrophotometer fitted with a fiber optic
probe (Varian, CA). Control wells were run with each trial and contained cells, media,
and XTT reagent.
The spectrophotometer generates absorbance values in arbitrary units.
Our % survival (relative to controls) values were determined by calculating the average
absorbance values of triplicate wells, then dividing that average by the average control
absorbance value for that trial. The 50% inhibitory concentration (IC50) values were
determined using a linear trendline generated by the Excel program (Microsoft). A
scatter plot of the cell viability data was created as a function of drug concentration, then
a linear trendline equation for each drug was determined by the software such that the xaxis depicted drug concentration values, and the y-axis depicted % survival (relative to
controls). The value of “50” was substituted for the “y” variable in the equation to obtain
the IC50 value.
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2.1.5

MTT Cell Viability Assay
Cell viability was also determined using the tetrazolium salt MTT Cell

Proliferation Assay Kit (Molecular Probes). The MTT assay operates under the same
principles as the XTT. The assay involves the conversion of the water soluble MTT (3(4,5-dimethylthaizol-2-yl)-2,5-diphenyltetrazolium bromide) into an insoluble purple
formazan dye. The amount of dye produced is proportional to the number of live cells.
The aqueous contents are then removed and the dye is then dissolved in DMSO and
quantified using a spectrophotometer.
After drug treatment as described in section 2.1.3, 20 uL of the MTT
reagent (5 mg/ml) was added to each well. Plates were incubated for an additional 3
hours at 37˚C with 7.5% CO2. The plates were then agitated on a plate shaker for
approximately 5 minutes. The liquid content of the wells were aspirated out and
discarded. To dissolve the dye product, 200 uL of DMSO was added to each well. The
plates were agitated again until the dye crystals were completely dissolved. Samples
were immediately analyzed for absorbance at 570 nm using a UV-visible
spectrophotometer (Varian, CA) with fiber optic probe. Control wells were run with each
trial containing cells, media, and MTT reagent. Relative survival and IC50 values were
calculated as described in section 2.1.4.
2.1.6

Nitric Oxide Production
The quantity of nitric oxide produced was determined using the DAF-FM

(4-amino-5-methylamino-2',7'- difluorofluorescein) Diacetate Reagent Kit (Molecular
Probes, OR). The DAF-FM diacetate assay is based on the reactivity of aromatic vicinal
13

diamines with nitric oxide (NO) in the presence of oxygen [70]. The non-fluorescent
DAF-FM diacetate passively diffuses through the cell membrane and is de-acetylated by
intracellular esterases to become DAF-FM. The reaction of the weakly fluorescent DAFFM with NO transforms DAF-FM to an intensely fluorescent benzotriaole derivative,
which can be measured for fluorescence using a fluorimeter [70, 71].

Figure 2.1 Mechanism of DAF-FM assay. Schema adapted from Molecular Probes
[72].

Drug treatment was performed as described in section 2.1.3 using phenolred free DMEM media (Biowhittaker). The DAF-FM diacetate reagent was prepared by
dissolving 50 ug of the reagent powder with 20 uL of molecular biology grade DMSO
[dimethylsulfoxide] (Fisher Scientific). The solution was then diluted with media to
produce a 105 uM working solution. Ten microliters of the working solution was added
to each well. The plates were incubated with the working solution (final DAF-FM
diacetate concentration = 5 uM) for 30-120 minutes at 37˚C with 7.5% CO2. The plates
were then agitated on a plate shaker and immediately analyzed for fluorescence via a
fluorescence spectrophotometer (Varian, CA). Fluorescence spectrophotometer settings
were as follows: excitation wavelength = 495 nm, emission wavelength = 515 nm,
14

excitation slit = 5 nm, and emission slit = 5 nm. Each treatment condition was performed
in triplicate. Control wells containing cells, media, and DAF-FM acetate were run with
each trial.

2.1.7

Western Blotting
To determine the expression level of inducible nitric oxide synthase

(iNOS) in cells, a Western Blot was performed. Cells were grown and treated at 40 uM
as described in sections 2.1.2 and 2.1.3. Cells were harvested by trypsinization and lysed
with a hypotonic buffer. Equivalent quantities of protein from each sample were
separated by SDS-PAGE on 4-15% Tris-HCl Ready Gels (Bio-Rad). Following
electrophoresis, proteins were transferred to Immobilon-P membranes (Millipore) using a
wet transfer method (Bio-Rad). Membranes were blocked for 1 h in 5% nonfat dry milk
in Tris-buffered saline-Tween-20 and subsequently washed. Membranes were incubated
with polyclonal iNOS antibody (Santa Cruz, SC-651) in 5% nonfat dry milk for 1 h.
Following washing, membranes were incubated with a secondary antibody in 5% nonfat
dry milk for 1 h. The signal was visualized by chemiluminescence using ECL reagent
(Amersham Biosciences) and then exposed to film. Band intensities were quantitated
using ImageQuant software (Molecular Dynamics) [73]. This blot was graciously run by
Laura Pendleton (Dept. of Biochemistry, USF).
To determine the levels of HIF-1α and VEGF expression, DU145 prostate
cancer cells were serum-starved for 20 h in serum-free media and treated with PH9 for 6
hours. Fifty µg of nuclear or whole-cell extracts was used. HIF-1α rabbit polyclonal
antibody (H-206) (1:500 dilution) and anti-VEGF monoclonal antibody (1:1,000 dilution)
15

were used for the Western blot. Horseradish peroxidase-conjugated sheep anti-mouse
and donkey anti-rabbit or anti-goat secondary antibodies were used at 1:2,000 and
1:5,000 dilutions, respectively. The signal was developed with SuperSignal West Pico
Chemiluminescent Substrate (PIERCE). These blots were kindly run by the Yu lab
(Dept. of Interdisplinary Oncology, Moffitt Cancer Center).

2.1.8

Energy-dispersive X-Ray Analysis of Platinum-Treated Cells
Localization of the intracellular platinum-based drugs was attempted with

electron microscopy. Cells were grown to confluence (~2-6 x 106 cells) as described in
section 2.1.2 in a sterile 10 cm2 glass Petri dish. Cells were incubated with 55 uM of
drug for 48 hours. The cells were then washed twice with 1x PBS and fixed overnight
with 2.5% glutaraldehyde in 0.1 M phosphate buffer at room temperature. The fixative
was aspirated and saved. The cells were rinsed with PBS, then dehydrated in a graded
series of ethanol as follows: 35% ethanol, 70% ethanol and 95% ethanol, 5 minutes each
at room temperature. Cells were then scraped from the Petri dish and infiltrated with a
50:50 mix of 95% ethanol:L R White acrylic resin in a microcentrifuge tube for 1 hour at
room temperature. The cells were infiltrated in two 1-hour changes of 100% L R White
at room temperature, then infiltrated overnight in L R White at 4˚C. The following day,
cells were incubated twice in fresh changes of L R W Localization of the intracellular
platinum-based drugs was attempted with electron microscopy. Cells were grown to
confluence (~2-6 x 106 cells) as described in section 2.1.2 in a sterile 10 cm2 glass Petri
dish. Cells were incubated with 55 uM of drug for 48 hours. The cells were then
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washed twice with 1x PBS and fixed overnight with 2.5% glutaraldehyde in 0.1M
phosphate buffer at room temperature. The fixative was aspirated and saved. The cells
were rinsed with PBS, then dehydrated in a graded series of ethanol as follows: 35%
ethanol, 70% ethanol and 95% ethanol, 5 minutes each at room temperature. hite at room
temperature. Following the last resin change, cells were placed in a gelatin capsule,
which was then filled with the resin. The resin was polymerized at 50˚C overnight (~15
hours).
Following polymerization, the block of cells was sectioned on a Reichert
Ultracut ultramicrotome using a diamond knife. Sections at 0.25 microns and 90 nm,
were obtained. The sections were picked up on 200 mesh nickel grids and examined
without further staining with a Philips CM10 transmission electron microscope equipped
with an EDAX 9900 energy-dispersive x-ray analyzer. The microscope was operated at
60 kV. A spot size of 100 nm was used to examine the cells. X-ray spectra from the
nuclei, cytoplasm and cell membrane were collected at a count rate of 250 cps. A
platinum aperture for the microscope was inserted into the beam to serve as a positiveplatinum control.
Additional cells were desiccated from either ethanol or distilled water onto
carbon sample holders and examined as bulk samples by scanning electron microscope
(SEM) with EDAX analysis. Dried cells were examined with and without a carbon
coating at 30 kV in a Philips 515 SEM with the EDAX analyzer. A spot size of 100 nm
was also used to collect x-ray data in the SEM. The cell nuclei and cytoplasm were
examined in this study. A drop of the fixative was also air-dried on a sample holder and
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examined by SEM-EDS to detect for possible levels of platinum that may have diffused
out of the cells.
The EDAX analyzer is able to detect concentrations of 0.5% for heavy
elements such as platinum. Under ideal conditions, the analyzer may detect levels as low
as 0.25% concentration of an element in a sample.

2.1.9

Electrophoretic Mobility Shift Assay (EMSA)
Cells were grown and treated with drugs as described in section 2.1.2 and

2.1.3. Nuclear extracts from the cells were used for electrophoretic mobility gel shift
assays (EMSA) as described by Turkson et al. [74]. Briefly, nuclear extracts containing
STAT3 and STAT1 were prepared from human lung non-small cell line A549, and preincubated with various concentrations of PH compounds for 30 minutes. Volumes
containing equal amounts of total protein were then incubated with 32P-labeled hSIE
oligonucleotide probe, which expresses high affinity sis-inducible elements that
selectively bind STAT1 or STAT3. The resulting DNA-protein complexes were
analyzed by EMSA for the STAT-related DNA-binding factors. This work was
performed by the Jove lab (Dept. of Interdisciplinary Oncology, Moffitt Cancer Center).

2.2

In vivo studies

2.2.1

Animal Housing and Treatment
Male, 8-week-old athymic mice used in these experiments were obtained

from Jackson Laboratories and were cared for in accordance with the guidelines of
IACUC under protocol #R2426 . Animals were caged in groups of four and housed in
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conventional condition in a temperature-controlled vivarium (23°C) on a reverse
light/dark cycle. Food and water were available ad libitum. The mice were acclimated to
the housing environment for 7 days prior to testing. At week 2 of the study, mice
received subcutaneous injections of A549 cells in PBS (1 x 107 cells/ flank) into the right
flank. Tumors grew to a palpable size by week 3.
Mice were randomly distributed into four groups of 12 mice. Three
treatment and one control group were defined as: (1) Group 1: drug treatment with 7 mg
PH9/kg body weight, (2) Group 2: drug treatment with 7 mg PH14/kg body weight, (3)
Group 3: drug treatment with 7 mg PH12/kg body weight, and (4) Group 4: control
treatment with saline. The treatment groups received a series of three 0.2 mL injections
of the drug dissolved in DMSO (20%) with saline vehicle (80%) into the tail vein. The
control group received only saline:DMSO vehicle. Blood from the saphenous vein was
collected from the animals weekly into heparin-gel tubes. Urine was collected during
routine weighings. All procedures were performed during the dark phase of the lightdark cycle. Animals were euthanized at the 8th week of the study and the organs were
harvested and frozen for future work.
One compound, PH9, was selected for further in vivo toxicity testing. Yu
et al carried out mouse studies as previously described [75]. Briefly, 7 to 8 week-old
C57BL/6 male mice (NCI, Frederick, MD) were maintained under pathogen-free
conditions in accordance with established institutional guidance and approved protocols.
The animals received subcutaneous injections of murine bladder tumor MB49 cells (5 x
105 cells/ flank) into the right flank. The tumors were allowed to grow to 3-5 mm in
diameter. Tumor sizes were recorded weekly with Vernier calipers. Over the course of
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two weeks, four tail vein injections of PH9 (5 mg/kg) were administered to the treatment
group. The control group received only vehicle (10% DMSO/PBS). Animals were
euthanized within 1-3 days of the last injection using a CO2 chamber. Blood was
immediately collected via cardiac puncture using a 1 cc syringe, and transferred in
heparin-gel tubes.

2.2.2

Toxicology
Analyses of toxicity were determined by quantifying levels of enzymes

and proteins present in blood and urine. The detection of glucose and glutamic acid
concentrations in the urine was mediated by an Amplex Red Glucose Assay Kit and
Amplex Red Glutamic Acid Assay Kit, respectively (Molecular Probes). All procedures
were conducted in accordance with the instructions provided by the manufacturer [76,
77]. Briefly, stock and working solutions were prepared by combining 1X reaction
buffer, horseradish peroxidase, and assay reagent. A standard curve was created by
diluting glucose in 1X reaction buffer. Each urine sample was diluted in 1X reaction
buffer. Fifty microliters of the working solution was added to microplate wells
containing 50 uL of sample or control specimen. The plates were incubated at either
room T in ambient air or at 37˚C with 7.5% CO2 depending on kit instructions. Plates
were agitated briefly on a plate shaker and then immediately measured for fluorescence
using a fluorescence spectrophotometer. Fluorescence spectrophotometer settings were
as follows: excitation wavelength = 530 nm, emission wavelength = 590 nm, excitation
slit = 5 nm, and emission slit = 5 nm. Background fluorescence was accounted for by
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subtracting control absorbance values from sample values. Glucose/glutamic acid values
were determined from the absorbance readings by comparison to the standard curve.
The detection of albumin, alanine aminotransferase (ALT), and blood urea
nitrogen (BUN) concentrations from serum samples was mediated by Amplex Albumin
Reagent, ALT Reagent, and BUN Reagent assay kits, respectively (Amresco). All
procedures were conducted in accordance with the instructions provided by the
manufacturer[78-80]. Briefly, blood samples were collected in heparin-gel blood
collection microtubes. The tubes were centrifuged at 2,000 xg for 10 minutes. Serum
was separated from the clot immediately and kept on ice or at 4˚C until analysis. Assays
were performed within 24 hours of blood collection. Working solutions were prepared
by reconstituting stock reagent powder with 50 uL deionized water. Working solution
was incubated for the designated time in a 37˚C water bath. Samples and controls were
added to the solution and incubated again. The absorbencies were measured by a UVvisible spectrophotometer with fiber optic probe at wavelengths unique to each assay kit.
Toxicological analysis of the 17 blood samples collected from C57BL/6
mice was performed using the Vitros 950 automated chemical analyzer (Ortho Clinical
Diagnostics).

2.2.3

Angiogenesis
To assess for the effect of PH9 on angiogenesis, athymic mice (NCI) were

maintained by Yu et al as described in section 2.2.5. Matrigel assays were performed as
described previously [81]. Briefly, 2 x 106 MCF-7 tumor cells stably transfected with
either an empty control vector or Stat3siRNA expression vector were suspended in 100 µl
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PBS and mixed with 0.5 ml of Matrigel (Collaborative Biochemical Products) on ice,
followed by injection subcutaneously into the abdominal midline of nude nice. Matrigel
plugs were harvested for photography and assaying hemoglobin contents. Hemoglobin
quantification was carried out by the Drabkin method.
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CHAPTER 3: RESULTS AND DISCUSSION

3.1

Cell Viability
Cell viability is a critical factor to consider when determining the effect of

a chemotherapeutic agent on cells. The use of XTT in the enumeration of viable cells
after drug treatment can indicate if the agent is effective in killing cells, but can also
indicate cytotoxicity as well [67, 82]. To identify the optimal experimental conditions,
preliminary data was generated from a range of treatment parameters at the beginning of
the study. An analysis of 14 novel nitroplatinum (IV) compounds and cisplatin at various
treatment concentrations revealed that cell viability was not markedly affected at
concentrations below 30 uM for all incubation times measured (data not shown). Cell
viability data for these compounds was also collected for a range of incubation times with
the XTT reagent. Table 3.1 summarizes the average relative survival values and standard
deviations for the drugs at incubations times of 2-5 hours at drug treatment concentration
of 50 uM. Absorbance data of treated cells is presented as % survival (treated absorbance
/ control absorbance). It was determined that incubation of the cells with the XTT
reagent between 3-5 hours yielded reliable data with the low standard deviations between
triplicate wells of the same treatment. This data lie within the range of the suggested
incubation times as recommended by the reagent manufacturer. These drug
concentrations and reagent incubation times were used in subsequent experimentations.
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Table 3.1 Relative survival for A549 cells treated with 50 uM PH compounds as a
function of XTT incubation time.
Drug
Cisplatin
PH1
PH2
PH3
PH4
PH5
PH6
PH7
PH8
PH9
PH10
PH11

2h
62.0 +/- 4.1
57.5 +/- 1.3
77.7 +/- 4.1
53.6 +/- 2.3
57.3 +/- 0.7
54.0 +/- 2.5
55.8 +/- 0.5
57.5 +/- 1.6
54.7+/- 1.4
54.9 +/- 0.7
54.0 +/- 0.5
56.1 +/- 0.1

3h
63.4 +/- 1.6
57.6 +/- 1.0
73.6 +/- 2.5
53.4 +/- 0.6
57.3 +/- 0.5
54.8 +/- 0.6
55.6 +/- 0.3
57.7 +/- 0.3
54.7 +/- 1.1
55.6 +/- 0.9
53.6 +/- 0.3
55.6 +/- 0.0

4h
62.2 +/- 0.4
56.7 +/- 1.0
73.4 +/- 1.1
52.0 +/- 0.7
55.6 +/- 0.6
53.5 +/- 0.7
54.3 +/- 0.5
56.8 +/- 0.7
54.2 +/- 0.7
54.2 +/- 0.9
52.7 +/- 0.9
55.2 +/- 0.1

5h
72.1 +/- 0.7
61.6 +/- 1.4
80.0 +/- 1.4
56.2+/- 1.0
60.7 +/- 0.9
58.4 +/- 1.1
59.2 +/- 0.8
62.9 +/- 0.7
58.8 +/- 1.2
58.6 +/- 1.0
56.5 +/- 0.8
59.3 +/- 0.2

Figure 3.1 Relative survival for cells were treated with PH1-4 and cisplatin.
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Twelve of the fourteen compounds were better cell proliferation inhibitors
than cisplatin when compared at the same concentration. This observation is in agreement
with other studies of platinum(IV) compounds [2, 83, 84]. As demonstrated in Figure
3.1, all cells treated with PH1-PH4 at concentrations of 50 uM and 75 uM had lower
survival percentages than cisplatin. Their calculated IC50 were also lower than that of
cisplatin. Table 3.2 shows the IC50 values for these drugs. This data suggests that lower
dosages of the PH compounds can be used to inhibit tumor cell growth when compared to
dosages of cisplatin. It is evident that the calculated IC50 value for PH4 is unlikely to be
a valid value. This error may be due to incorrect drug dosing or improper cell distribution
during experimentation. Analyses for PH4 were repeated in later experiments.
Table 3.2 Calculated IC50 values for PH1-4 and cisplatin from XTT Assay.
Drug
Calculated IC50 (uM)
Cisplatin
80
PH1
31
PH2
41
PH3
-405
PH4
76
Subsequent trials run with these and other PH compounds resulted in
similar inhibition effects as compared to cisplatin. Figures 3.2 and 3.3 depict the percent
survival percentages for compounds PH4-11. Again, the novel compounds performed
significantly better than cisplatin. At concentrations of 60 uM or greater, there is almost
no survival of cells. Table 3.3 summarizes the IC50 values for these drugs. Cisplatin has
an IC50 of 71 uM, while the PH compounds inhibited 50% of the cell growth at
concentrations near 45 uM. The IC50 values for the PH compounds are consistently
lower than that of cisplatin.
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Figure 3.2 Relative survival for cells were treated with PH4-8 and cisplatin.
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Figure 3.3 Relative survival for cells were treated with PH1-3, 9-11 and cisplatin.
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Table 3.3 Calculated IC50 values for PH1-11 and cisplatin from XTT Assay.
Drug
Cisplatin
PH1
PH2
PH3
PH4
PH5
PH6
PH7
PH8
PH9
PH10
PH11

Calculated IC50 (uM)
71
44
48
43
47
43
46
48
47
43
46
47

Figure 3.4 depicts the relative survival percentages for four of the
previously tested compounds and three other compounds PH12-14. This experiment
gathered conflicting data as compared to the previous studies. The activity of cisplatin
appeared to be better than that of both the previously characterized novel compounds and
the untested compounds. IC50 values for the nitroplatinum (IV) compounds were also
significantly higher than values previously shown, though cisplatin actually demonstrated
a lower IC50 value. Table 3.4 shows these results.
The ligands of compounds PH12 and PH14 are structures which may
potentially have a proliferative affect on cells, in agreement with the results. However, in
this set of data, better proliferation is observed for the other PH compounds that had
previously been found to be efficient inhibitors of tumor cell growth. This observation,
suggests that the discordant data from this trial may is questionable. Possible sources of
error include equipment malfunction, technical mistakes, and unfavorable environmental
conditions for study. It can also be considered that the data from Figure 3.1 – 3.3 may
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Figure 3.4 Relative survival for cells were treated with PH3,4,9-14 and cisplatin.
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Table 3.4 Calculated IC50 values for PH3,4,9-14 and cisplatin from XTT Assay.
Drug
Calculated IC50 (uM)
Cisplatin
47
PH3
90
PH4
68
PH9
545
PH10
57
PH11
56
PH12
191
PH13
107
PH14
58
not be reliable, and further studies need to be conducted to produce repeatable, reliable
results for all compounds.
Assays of cell viability performed with MTT showed similar results to the
earlier XTT assays. Table 3.5 summarizes representative data from the MTT assays.
The calculated IC50 values for most compounds closely resemble those from the XTT
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Table 3.5 Calculated IC50 values for PH1,3,4,7-11 and cisplatin using the MTT assay.
Drug
Cisplatin
PH1
PH3
PH4
PH7
PH8
PH9
PH10
PH11

Calculated IC50 (uM)
63
50
41
56
61
506
45
54
53

assay, suggesting that there is agreement between the two assay types and thus that the
data is reliable. This agreement can implicate key drugs that should be further explored.
A summary of the IC50 values for the XTT and MTT assays are shown in
Table 3.6. Despite the conflicting results from XTT3 (data from third XTT trial), the
overall data suggests that some of these PH compounds may have the potential to serve
Table 3.6

Summary of calculated IC50 values from XTT and MTT assays.
XTT1
XTT2
XTT3
MTT
Avg +/- SD
Cisplatin
80
71
47
63
65.3 +/- 12.1
PH1
31
44
50
41.7 +/- 7.9
PH2
41
48
44.5 +/- 3.5
PH3
43
90
41
58.0 +/- 22.6
PH4
76
47
68
56
61.8 +/- 11.1
PH5
43
43
PH6
46
46
PH7
48
61
54.5 +/- 6.5
276.5 +/PH8
47
506
229.5
PH9
43
545
45
211 +/- 236.2
PH10
46
57
54
52.3 +/- 4.6
PH11
47
56
53
52.0 +/- 3.7
PH12
191
191
PH13
107
107
PH14
58
58

29

as potent anti-tumor agents at low doses. The enhanced activity of the PH compounds as
compared to cisplatin may be due to the action of the additional ligands on the novel
compounds which are not present in cisplatin. The additional activities of these
compounds are investigated in subsequent sections.
3.2

Nitric Oxide Production
As the platinum(IV) compounds reduce to a platinum(II) state in the cell,

the release of its axial nitro-ligands is expected [6]. These ligands eventually form nitric
oxide, which has been shown to have potent anti-tumor activities [40]. An assessment for
the presence of NO was mediated by the DAF-FM diacetate assay. Initial trials of this
assay were performed with media containing phenol-red. It was later discovered that
phenol-red media may interfere with fluorescence readings[72]. These data sets were
discarded. Unexpected problems also arose with the alignment of the plate reader of the
fluorimeter during this study. Efforts were made to rectify the fluorescence interference
by replacing the standard media with phenol-red free media during the drug treatment
phase of the experiment. The plate reader was re-aligned and tested for operation using
fluorescein (excitation wavelength = 492 nm, emission wavelength = 519 nm, excitation
slit = 5 nm, and emission slit = 5 nm).
Results from the DAF-FM diacetate assays are inconclusive. Figure 3.5A
shows the results of a DAF-FM diacetate assay after incubation with the reagent for 120
minutes. The level of NO production does not appear to have a dose-response
relationship until the drug concentration reaches 40 uM. After this point, the amount of
NO production correlates with drug dose. This phenomenon may be related to the data
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from proliferation assays showing that at drug concentrations of 30 uM and below, cell
survival is relatively unaffected. This suggests that the PH compounds had little effect on
NO production at concentrations below 40 uM. Thus, if these compounds are causing
NO release, the % NO production should be comparable to the control NO production, or
near 100%. However, most levels fall below 100%. At higher drug concentrations, the
Figure 3.5A Trial 1 results of NO production.
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PH compounds will begin to play a role in the production of NO. As drug concentration
increases, cell survival drops. Since the data of NO production represents each well and
not the rate per cell, it is expected that the relative NO production percentages
underestimate true values because there are fewer cells per treated well as compared to
control wells. Therefore, the dose-response relationship is expected to be even stronger
than shown in Figure 3.5A. Relative to cisplatin, only cells treated with PH3, PH11, and
PH13 seem to exhibit greater NO release. It cannot be determined at this time if these
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compounds are effective NO producers since their values as compared to controls have
not been correlated with cell number.
It is evident that the standard deviations of the data points as depicted by
the error bars are large. This variation is believed to be due to the extreme sensitivity of
the assay reagent, and the possibility of small variations in the number of cells between
wells. This standard deviation was observed in the controls as well. It is important to
note that fluorescein, which was included in the fluorimeter readings to control for read
error, showed very little deviation between triplicate wells (data not shown). This
observation demonstrates that inaccuracy of fluorimeter readings can be eliminated as a
source of error.
Figures 3.5B-D show the results of additional DAF-FM assays. The data
here does not provide insight into the abilities of these compounds to induce NO release.
Figures 3.5B and 3.5C indicate that cells treated with all compounds including cisplatin
had higher NO release than untreated control cells. However, results depicted in Figure
3.5D concurs with the data from Figure 3.5A in that the PH compounds were ineffective
in eliciting NO release. It is apparent that there is little agreement for % NO production
values between the various trials, but there is evidence that cisplatin treated cells generate
higher NO values than the PH compounds. This outcome was not expected since some of
the PH compounds were designed for this purpose. However, these results do not
conclusively indicate that the PH compounds are ineffective generators of NO, but rather
that further studies need to be conducted to accurately measure NO production.

32

Figure 3.5B Trial 2 results of NO production.
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Figure 3.5C Trial 3 results of NO production.
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50

Figure 3.5D Trial 4 results of NO production from cells.
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3.3

Nitric Oxide Synthase Expression
A Western blot analysis was performed to detect the expression of

inducible nitric oxide synthase (iNOS) in treated and untreated cells. Figure 3.6
summarizes the relative iNOS expression (normalized to B-actin) after 48 hour treatment
with PH compounds and cisplatin. All cells treated with PH compounds and cisplatin
demonstrated higher iNOS values than control cells. iNOS is known to produce a high
concentration of NO in tissues. Tumor cells that produce high levels of NO die in vivo
[49]. Furthermore, studies have reported that an inverse relationship exists between the
expression level of iNOS and the metastatic potential of murine tumor cells [48, 85-87].
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These reports, in conjunction with our results, suggest that high levels of cellular NO
production resulting from PH treatment may contribute to antitumor activity and
decreased metastatic potential.

Figure 3.6 iNOS expression of PH treated cells.
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Toxicology
Due to mechanical errors, sample contamination, inconsistent collection

practices, and reagent sensitivity, the blood serum data collected from the nude mice
were deemed unreliable and thus excluded from analysis for this study. This decision
was based on the generation of many negative values when assessing for blood enzymes,
which is clearly erroneous. Toxicological profiles were thus developed from the animal
groups from Yu et al.
Serum obtained at euthanasia was analyzed by the Vitros 950 automated
chemical analyzer (Ortho Clinical Diagnostics). The biochemical profile of Mouse PH935

1.1 from Day 1 was excluded from analysis due to a hemolyzed blood sample. C57BL6
mice from Day 1 showed the most abnormal blood chemistry values (Table 3.7). This
was expected as these animals have the highest dose of drug in their bodies. As the drug
is eliminated from their systems, the biochemical profiles of mice from Days 2-3 return
Table 3.7 Biochemical blood serum profiles for the assessment of toxicity.

Day 1

Day 2

Day 3

Normal
Control 1.1
Control 1.2
Control 1.3
PH9-1.1
PH9-1.2
Control 2.1
Control 2.2
Control 2.3
PH9-2.1
PH9-2.2
Control 3.1
Control 3.2
PH9-3.1
PH9-3.2
PH9-3.3
PH9-3.4
PH9-3.5

BUN
14-25
18.0
18.7
16.0
60.8
16.0
21.0
18.0
15.0
20.0
15.4
20.0
19.0
18.0
22.0
20.0
21.0
14.0

albumin
2.6-3.3
1.8
1.7
1.6
1.3
1.8
2.6
1.8
2.3
1.6
2.1
2.3
2.5
2.3
2.4
1.9
2.4
2.3

Creatinine
0.5-0.9
0.4
0.4
0.5
1.0
0.4
0.3
0.6
0.2
0.4
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.2

AST
66-170
96.0
325.3
192.0
339.2
252.0
81.0
122.0
119.0
78.0
190.3
54.0
87.0
161.0
273.0
84.0
139.0
347.0

ALT
24-140
78.0
98.7
101.3
224.0
272.0
46.0
66.0
88.0
76.0
68.6
35.0
61.0
70.0
259.0
44.0
53.0
101.0

closer to normal values. Normal ranges were determined from a variety of literature
sources, so it should be noted that values will vary according to breed, age, sex, sampling
technique, and quality of blood sample [88]. Therefore, interpretations are not definitive.
Blood urea nitrogen (BUN) and albumin levels are used to assess kidney
function. Elevated BUN levels may indicate kidney failure, disease, and dehydration.
Elevated albumin levels may indicate dehydration. Thus, if high albumin levels are noted
in conjunction with other elevated values, it should be considered that the out-of-range
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values are due to dehydration and not necessarily organ damage. Creatinine is the end
product of phosphocreatine metabolism, an enzyme associated with muscle contractions.
If elevated creatinine levels are observed with elevated BUN, kidney disease is often
implicated.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
levels are used to assess liver damage. AST is an indicator of the breakdown and
elimination of nitrogen. Low AST levels may indicate starvation or malnutrition, while
high levels may suggest liver damage, muscle damage, and inflammation. ALT is also
involved with nitrogen metabolism and is most often associated with liver function. Low
levels suggest starvation or malnutrition, while high levels indicate liver damage, toxin
ingestion, and various metabolic disorders. Low creatinine levels indicate liver disease or
starvation, while high levels may suggest dehydration, or kidney failure or disease.
Figure 3.6 graphically displays the biochemistry profiles of the blood
collected from mice one day after the treatment injection. Although the control mice
demonstrated individual blood chemistry values that may indicate toxicity, there was
insufficient data across the various blood panels that could collectively suggest that there
was any organ disease or damage. It is also evident that low albumin levels are observed
for nearly all control and treated mice. One of albumin’s functions is to transport drugs
within the blood stream [89, 90]. It has been shown that albumin is reactive to
platinum(II) complexes due to its thiol group [6]. Thus, low albumin levels may be
anticipated with platinum treatment. Mouse PH9-1.2 had high levels of AST and ALT,
and low albumin and creatinine. This finding may suggest that the administration of 5
mg/kg of PH9 to the animals may cause undesirable toxic side effects, and that a lower
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Figure 3.7 Biochemical blood profiles of mice one day after 5 mg/kg drug injection.

dose may need to be considered to prevent organ damage while sustaining the drug’s
anti-tumor action. Figure 3.8 displays the biochemistry profiles of the blood collected
from mice two days after the last injection. Creatinine and albumin levels were again low
for both treated and control mice, but other data did not support toxicity concerns. It was
concluded that low creatinine levels were not suggestive of liver disease. However, the
blood profile of PH9-2.2 of Day 2 demonstrates low creatinine and albumin in
conjunction with high AST (but normal ALT), possibly indicative of liver damage.
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Figure 3.8 Biochemical blood profiles of mice two days after 5 mg/kg drug injection.

Figure 3.9 displays the biochemistry profiles of the blood collected from
mice three days after the treatment injection. Again, only the data from the treated
animals indicate possible liver toxicity. PH9-3.2 and PH9-3.5 had low values of
creatinine and albumin, and high values of liver enzymes that suggested liver damage.
The control animals did not exhibit overall signs of toxicity.
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Figure 3.8 Biochemical blood profiles of mice three days after 5 mg/kg drug injection.

Cisplatin has been known for its induction of renal toxicity. Preclinical
studies of cisplatin performed on mice reported that significant kidney damage was
associated with the treatment [91, 92]. Leleiveld et al found levels of BUN and
creatinine in cisplatin-treated C57BL mice (6.7-10.0 mg/kg) to be nearly five times the
levels found in untreated animals on the fourth day after treatment [91]. These PH9
treated animals demonstrated no signs of nephrotoxicity. Table 3.8 compares our BUN
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Table 3.8 Creatinine and BUN values of mice after cisplatin or PH9 treatment.
BUN
Creatinine
Cisplatin
nmol/L
Nmol/L
Control
8.6 +/- 0.1
58.5 +/- 0.6
6.7 mg/kg cisplatin
55.0 +/- 15.0
281.0 +/- 88.0
10.0 mg/kg cisplatin 72.0 +/- 12.0
282.0 +/- 55.0
PH9
mg/Dl
mg/dL
Control
18.2 +/- 2.0
0.4 +/- 0.2
5 mg/kg PH9
18.3 +/- 2.9
0.3 +/- 0.1
and creatinine values with those values reported from cisplatin. It is evident that PH9
treated mice did not exhibit any measurable signs of kidney disease. Values of the
treated animals are similar to values of untreated animals. This evidence suggests that
PH9 may reduce toxicity relative to cisplatin.

3.5

X-Ray Diffraction
X-ray analysis of the platinum-treated cell block from the TEM was

unable detect a platinum signal anywhere in the cells. A spectra generated from the
positive-platinum control confirmed that the x-ray detector was functional. Energy
emission signals from the analysis of treated cells showed the presence of sulfur,
phosphorus and chlorine cells. The emission spectra also indicated the presence of silica
in the resin.
X-ray analysis of the platinum-treated bulk sample from the SEM was
unable to detect a platinum signal anywhere in the cells. Analysis of the fixative and the
drug also suggested that there was no platinum in the sample.
This data indicates that the level of platinum in the cells and culture
medium after treatment and fixation was below the minimum level of detectability for the
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x-ray analyzer. Another mode of analysis with lower limits of detection that may be
more sensitive may be necessary to detect and quantify the amount of platinum present in
the cells. Alternatively, platinum localization may require the analysis of cellular
organelles though the lysis of large numbers of treated cells. This may be mediated by
atomic absorption or inductively-coupled plasma.

3.6

Inhibition of STAT Dimerization
The PH compounds were able to inhibit acellular dimerization of STAT

proteins at concentrations as low as 0.3 uM. At concentrations of 30 uM, complete
inhibition of STAT dimerization was observed for all PH compounds. The IC50 for
STAT dimers by these compounds are summarized in Table 3.9.

Table 3.9 Calculated IC50 values of PH compounds for STAT dimerization.
Compound
STAT3:STAT3 (uM)
STAT1:STAT3 (uM) STAT1:STAT1(uM)
PH4
0.5
1.0
1.0
PH1
0.5
1.0
1.0
PH10
2.0
2.2
0.5
PH7
0.4
0.4
0.4
PH11
0.3
0.4
0.4
Previous studies with other inhibitors of STAT report that much higher
concentrations are necessary to achieve the same effect. Blaskovich et al found that JSI124 (Ccurbitacin I) had an IC50 value of 500 nm in the human lung carcinoma A549 cell
line [93]. Grandis et al used antisense oligonucleotides to inhibit STAT at 12.5 uM. It is
evident that the IC50 values of the PH compounds are effective at lower concentrations,
suggesting that these PH compounds may be superior STAT inhibitors. However, since
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this assay was conducted with nuclear extracts and not whole cells, cellular transport and
other mechanisms and other mechanisms will activities in vivo.

Figure 3.10 Inhibition of STAT dimerization by PH compounds.

Assessment of the effects of the PH compounds on other STAT dimers is
critical in understanding the compounds’ effects on other signaling cascades. Though the
PH compounds were effective at preventing STAT3:STAT3 binding, the STAT1
homodimer is less affected at concentrations below 10 uM (Figure 3.10). It has been
shown that STAT1 activation is elevated in a few cancers, but its function has mostly
been observed as growth suppression rather than malignant transformation [94] . Thus,
the preservation of the STAT1 dimerization function is desirable in maintaining its
actions as a potential tumor suppressor. The STAT1:STAT3 heterodimer has been
weakly linked to similar effects of constitutively active STAT3, so its inhibition
continues to be a desired effect.
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3.7

Angiogenesis
As shown in Figure 3.11, Yu’s group at Moffitt revealed that Western Blot

analysis of cells treated with PH9 resulted in decreased HIF-1α and VEGF expression.
Lanes 1-4 denote the concentration of PH9 administered. B-actin is a housekeeping gene

Figure 3.11 Determination of HIF-1α, VEGF, and STAT3 expression by Western blot.
PH9 affects HIF-1α and VEGF expression in a dose-dependent manner (top gel). This
reduction of expression can be correlated with STAT3 expression (bottom gel).

that normalizes the amount of protein in each well to maintain consistency for analysis
between lanes. The intensity of HIF-1α and VEGF bands fades across the lanes,
indicating that PH9 affects the expression of these proteins in a dose-dependent manner.
This reduction in expression of HIF-1α and VEGF correlates with the expression of
STAT3, suggesting a relationship. As STAT3 expression decreases, HIF-1α and VEGF
expression decreases as well. This data is in agreement with the data found in section
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3.7, where PH9 was found to reduce STAT3 activity. Since the over-expression of
VEGF and HIF-1α is associated with tumor angiogenesis, tumor cell proliferation and
invasion, PH9 may be an inhibitor of critical angiogenic proteins, possibly related to
STAT3 inhibition.
Further in vivo studies verified that treatment the blocking with PH9
resulted in reduced microvessel density. Matrigel-implanted human breast carcinoma
MCF-7 tumors from PH treated mice were excised and analyzed for angiogenesis.
Figure 3.12 Matrigel plugs of MCF-7 tumors.

Figure 3.12 shows control and PH9 treated Matrigel plugs of MCF-7 tumors that were
harvested 5 days after implantation. Mice treated with the DMSO vehicle demonstrate

increased neovasculature as compared to mice treated with PH9. Further studies
identifying mechanistic pathways are in progress in collaborations with the Yu lab.

3.8

Tumor Growth Inhibition
In vitro studies conducted by Yu’s group indicated that MB49 cells did not

respond to PH9 treatment [95]. However, mice treated with PH9 demonstrated inhibited
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MB49-tumor growth. Within 5 days of tumor induction, a palpable mass was detected
for control and experimental mice. Tumors continued to grow throughout the drug

Figure 3.13 Tumor size (mm3) of control and PH treated mice.

regimen for both groups. Animals treated with PH9 exhibited significantly slower
growth and smaller tumors as compared with control animals (Figure 3.13). Because the
same cell line used in vitro did not respond to PH9 treatment, it is believed that the tumor
inhibition was due to an immunological or systemic response to the drug. These facts
suggest that PH9 may be used as an effective chemotherapeutic agent to inhibit tumor
growth.
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CHAPTER 4: CONCLUSION

In an effort to overcome common problems associated with the traditional
methods of cisplatin cancer treatment, we have synthesized novel chemotherapeutic
agents designed to circumvent drug-resistance and toxic side effects, while achieving
improved activity by targeting unique pathways unique to cancer. We focused on
obtaining preliminary data to characterize these compounds in order to elucidate potential
compounds for further study. In vitro and in vivo studies were performed to describe
their activities.
Table 4.1 summarizes the results of key assays performed on the PH
compounds. Data not shown in this table include toxicity and angiogenesis findings,
since only PH9 was examined in those assays. Cell proliferation assays performed from
XTT and MTT tetrazolium salt reagents showed that all PH compounds, with the
exception of PH12 and PH13, exhibited lower IC50 values than that of cisplatin.
Western blot analyses of iNOS expression demonstrated that PH3 and PH11 treated cells
had greater iNOS expression than cisplatin. All compounds that were tested for
inhibition of STAT3 dimerization had IC50 values of 2 uM or lower. Contrary to the
nephrotoxicity commonly observed in cisplatin-treated mice, our toxicological analysis of
PH9 treated mice indicated that no kidney damage was evident. However, elevated livr
enzymes were measured, warranting further studies. Additionally, PH9 exhibited anti-
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Table 4.1 Comparison of the results of various assays on PH compounds.
Compound
Avg IC50 (uM)
Relative iNOS
STAT3
expression
IC50 (uM)
Cisplatin
65.3 +/- 12.1
1.64
---PH1
41.7 +/- 7.9
---0.5
PH2
44.5 +/- 3.5
------PH3
58.0 +/- 22.6
2.19
---PH4
61.8 +/- 11.1
1.56
0.5
PH5
43
------PH6
46
------PH7
54.5 +/- 6.5
---0.4
PH8
276.5 +/- 229.5
------PH9
211 +/- 236.2
1.23
---PH10
52.3 +/- 4.6
1.55
2.0
PH11
52.0 +/- 3.7
1.99
0.3
PH12
191
------PH13
107
1.37
---PH14
58
1.10
---angiogenesis properties, as demonstrated by the inhibition of HIF-1α and VEGF
expression. These assays have identified PH3, PH9, and PH11 as the most promising
candidates for further studies.
These nitroplatinum(IV) compounds are also expected to circumvent the
resistance seen with cisplatin since their novel mechanisms may not involve DNA
binding and therefore evades the DNA mismatch repair mechanism. These data suggest
that these novel nitroplatinum compounds may serve as effective alternatives to cisplatin.
Further studies will refine the data established in this study. Future work
will include the determination of the spectrum of activity of the PH compounds in various
cell lines. We also hope to identify the optimal dose by conducting further cell viability
assays and toxicology studies. Additionally, the structures of the platinum complexes
must be verified using x-ray crystallography. Nitric oxide production may be assessed
with further Western blotting for iNOS. Lastly, we wish to explore STAT3 inhibition
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and anti-angiogenesis mechanisms for PH3 and PH11. This additional work may reveal
future directions into clinical trials.
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